Epidermal growth factor receptor (EGFR) in Biliary tract cancer

Gomes, Rodrigo Vieira; Vidigal, P.T.; Damasceno, Karine Araújo; Rodrigues, Michele Ângela; Resende, Vívian

doi:10.1016/j.hpb.2016.03.227

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR (synonym ErbB1, HER1) plays a crucial role in cancer proliferation, cell mortality, angiogenesis, cell adhesion, and metastasis through multiple downstream pathways (ERK/MAPK, PI3K-AKT, SRC, PLC-γ1-PKC, JNK, JAK-STAT) [ 115 , 116 , 117 ]. The overexpression of EGFR in GBC is common, with a frequency of 44–77% [ 118 , 119 , 120 ], and is associated with a worse prognosis [ 121 ]. At the moment, data on the effect of anti-EGFR therapy in GBC patients is disappointing.…”

Section: Therapymentioning

confidence: 99%

Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions

Sturm

Schuhbaur

Hüttner

et al. 2022

Cancers

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is the most common primary tumor site of biliary tract cancer (BTC), accounting for 0.6% of newly diagnosed cancers and 0.9% of cancer-related deaths. Risk factors, including female sex, age, ethnic background, and chronic inflammation of the gallbladder, have been identified. Surgery is the only curative option for early-stage GBC, but only 10% of patients are primary eligible for curative treatment. After neoadjuvant treatment, up to one-third of locally advanced GBC patients could benefit from secondary surgical treatment. After surgery, only a high-risk subset of patients benefits from adjuvant treatment. For advanced-stage GBC, palliative chemotherapy with gemcitabine and cisplatin is the current standard of care in line with other BTCs. After the failure of gemcitabine and cisplatin, data for second-line treatment in non-resectable GBC is poor, and the only recommended chemotherapy regimen is FOLFOX (5-FU/folinic acid and oxaliplatin). Recent advances with the PD-L1 inhibitor durvalumab open the therapy landscape for immune checkpoint inhibition in GBC. Meanwhile, targeted therapy approaches are a cornerstone of GBC therapy based on molecular profiling and new evidence of molecular differences between different BTC forms and might further improve the prognosis of GBC patients.

show abstract

Section: Therapymentioning

confidence: 99%

Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions

Sturm

Schuhbaur

Hüttner

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The overexpression population of EGFR in GBC was observed between 44 and 77% of patients in different independent studies. [133][134][135] Elevated expression of EGFR in GBC tissues was positively correlated with poor prognosis of the patients. 136 We also found that somatic mutations of EGFR were quite low ranging from 2.5 to 3.9% in GBC patients.…”

Section: Her2mentioning

confidence: 99%

Overview of current targeted therapy in gallbladder cancer

Song

et al. 2020

Sig Transduct Target Ther

103

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor. Unfortunately, only a small population of cancer patients is acceptable for the surgical resection, the current effective regimen; thus, the high mortality rate has been static for decades. To substantially circumvent the stagnant scenario, a number of therapeutic approaches owing to the creation of advanced technologic measures (e.g., next-generation sequencing, transcriptomics, proteomics) have been intensively innovated, which include targeted therapy, immunotherapy, and nanoparticle-based delivery systems. In the current review, we primarily focus on the targeted therapy capable of specifically inhibiting individual key molecules that govern aberrant signaling cascades in GBC. Global clinical trials of targeted therapy in GBC are updated and may offer great value for novel pathologic and therapeutic insights of this deadly disease, ultimately improving the efficacy of treatment.

show abstract